Drug Profile
Research programme: macrocyclic peptide therapeutics - Eli Lilly and Company/PeptiDream
Latest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Eli Lilly and Company; PeptiDream
- Developer PeptiDream
- Class Macrocyclic compounds; Peptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for research development in Undefined in Japan
- 07 Mar 2016 Peptide discovery platform system (PDPS) technology non-exclusively licensed to Eli Lilly and Company in USA
- 19 Dec 2013 Early research in Undefined indication in Japan (unspecified route)